Editas Medicine Inc. (EDIT) Confirms EDT-401 as Lead Vivo Program

Editas Medicine Inc. (NASDAQ:EDIT) is one of the best performing penny stocks to buy now. On September 5, HC Wainwright reiterated a “Buy” rating on the stock and a $5 price target. The positive stance follows the nomination of EDIT-401 as the company’s lead Vivo program.

The company is developing EDIT-401 as a one-time therapy for reducing LDL cholesterol levels. The company is developing the program as an experimental, transformative in vivo gene editing medicine based on an upregulation approach.

EDIT-401 is designed to treat hyperlipidemia by directly editing the LDLR gene to increase LDLR protein expression and reduce LDL-C levels. Its nomination as a lead in vivo development candidate marks a significant milestone in Edita’s long-term vision to lead the field of in vivo programmable gene editing.

“At Editas Medicine, we believe in vivo is the future of medicine. With EDIT-401, we’re advancing our differentiated upregulation strategy to develop a next-generation medicine that can deliver lasting impact for patients,” said Gilmore O’Neill, Chief Executive Officer of Editas Medicine.

Editas Medicine Inc. (NASDAQ:EDIT) is a genome-editing company that develops transformative medicines for individuals with severe, genetically defined diseases using CRISPR-based technology. The company focuses on discovering, developing, and commercializing durable, precise, in vivo (within the body) gene-editing therapies that can correct or modify disease-causing genes.

While we acknowledge the potential of EDIT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Healthcare Penny Stocks to Buy Now and 11 Best AI Stocks to Buy Under $5

Disclosure: None. This article is originally published at Insider Monkey.